STOCK TITAN
  1. Home
  2. News
  3. 2026-10-25

Stock Market News for October 25, 2026

17 stories published so far on Sunday, October 25, 2026.

The day runs on New York time, and each time in the list shows the time zone it is in.

US stock markets are closed on this day. News from the last trading session is on Friday, October 23, 2026.

RSS Feed Add StockTitan on Google Add to Google Follow on Google News

This list is a snapshot of the day and does not update by itself. Bookmark it for the day’s company news, or open the live news feed, which adds new headlines without a reload.

Sat, Oct 24
IMPACT
SENTIMENT
ORKA : Nasdaq
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
conferences
IMPACT
SENTIMENT
SMMT : Nasdaq
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
high short
IMPACT
SENTIMENT
AZN : NYSE
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
IMPACT
SENTIMENT
AZN : NYSE
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
IMPACT
SENTIMENT
RHHBY : OTC
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
IMPACT
SENTIMENT
JNJ : NYSE
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
IMPACT
SENTIMENT
AVBP : Nasdaq
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
clinical trial
IMPACT
SENTIMENT
AMRN : Nasdaq
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
clinical trial low float
IMPACT
SENTIMENT
GMAB : Nasdaq
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
clinical trial
IMPACT
SENTIMENT
AGEN : Nasdaq
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
clinical trial
IMPACT
SENTIMENT
NBP : Nasdaq
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
clinical trial penny stock
IMPACT
SENTIMENT
BORR : NYSE
Borr Drilling Limited - Prospector 5 Rig Incident
IMPACT
SENTIMENT
REGN : Nasdaq
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
IMPACT
SENTIMENT
XNCR : Nasdaq
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
clinical trial high short
IMPACT
SENTIMENT
LLY : NYSE
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
IMPACT
SENTIMENT
JNJ : NYSE
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
IMPACT
SENTIMENT
BNTX : Nasdaq
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
clinical trial
Sat, Oct 24

You can use the feed to follow a portfolio or watchlist, research a company, or catch up on developments around shares you own.

It keeps the day's company news in one place, with the dated archive available when you need an earlier session.

What this page covers